Results 131 to 140 of about 163,209 (266)

Dermatitis Artefacta [PDF]

Proceedings of the Royal Society of Medicine, 1930
openaire   +5 more sources

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Exploring the link between atopic dermatitis and allergic contact dermatitis in patients with skin of color: a scoping review. [PDF]

Int J Womens Dermatol
Mallett JR, Lee CM.
europepmc   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

A Silicone-Based Film-Forming Gel Wound Dressing for Radiation Dermatitis in Head and Neck Cancer Patients: A Retrospective Cohort Analysis Using Clinical Informatics. [PDF]

Cureus
Liu EY, Jank E, Courtney PT, Juarez J, Ma TM, Delery W, Chau L, Reddy V, Sim MS, Chin RK, Savjani RR.   +10 more
europepmc   +1 more source

Assessing Targeted Proteomics in Inflammatory Skin Diseases with the Tape-stripping Method. [PDF]

Acta Derm Venereol
Vinge AS, Altintas S, Ødum N, Johansen JD, Løvendorf MB, Skov L.   +5 more
europepmc   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Subcutaneous immunoglobulin-induced eczematous dermatitis

JAAD Case Reports
Rachel Breidbart, BS, Matthew D. Vesely, MD, PhD   +1 more
doaj   +1 more source

Trends and projections of dermatitis burden (1990-2040): a 2021 global burden of disease analysis. [PDF]

Front Med (Lausanne)
Fang J, Chen G, Wu M, Shi Y, Yuan C, Liu W.   +5 more
europepmc   +1 more source

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

JEADV Clinical Practice, EarlyView.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio, Gabriele Roccuzzo, Iria Neri, Alessandro Pileri, Alessandro Svizzero, Maria Beatrice De Felici Del Giudice, Vieri Grandi, Pietro Quaglino, Valeria Brazzelli   +8 more
wiley   +1 more source